ライフサイエンスコーパス: esophagogastric

1 1.6% of all patients, most frequently after esophagogastric (4.2%) and hepatopancreaticobiliary (3.6

2 mal growth factor receptor 2 (HER2)-positive esophagogastric adenocarcinoma (EGA).

3 improves survival in patients with advanced esophagogastric adenocarcinoma and undifferentiated carc

4 onditioning, a side-to-side stapled cervical esophagogastric anastomosis (<3% incidence of leak), and

5 An esophagogastric anastomosis was performed in 144 patient

6 Transhiatal esophagectomy with a cervical esophagogastric anastomosis was performed on approximate

7 ed blood flow to the gastric fundus prior to esophagogastric anastomosis.

8 Complications included esophagogastric anastomotic leak (n = 15, 36%), which un

9 anitumumab for Advanced and Locally Advanced Esophagogastric Cancer (REAL-3) will evaluate whether th

10 tandard of care for patients with resectable esophagogastric cancer.

11 ne (EOC) is a standard treatment in advanced esophagogastric cancer.

12 these innovations, portosystemic shunts and esophagogastric devascularization remain important and e

13 mmon indications for nonselective shunts and esophagogastric devascularization were medically intract

14 renal shunt (DSRS), nonselective shunts, and esophagogastric devascularization, was taken.

15 more protective against rebleeding than was esophagogastric devascularization.

16 roesophageal reflux disease (GERD) and other esophagogastric diseases.

17 Transoral esophagogastric fundoplication (TF) can decrease or elim

18 Increasing numbers of patients are failing esophagogastric fundoplication and requiring redo proced

19 CC) of the esophagus, adenocarcinomas of the esophagogastric junction (AEG), or gastric cancer (GC).

20 .0) versus sham on esophageal physiology and esophagogastric junction (EGJ) anatomy.

21 Adenocarcinoma of the esophagus and esophagogastric junction (EGJ) is increasing, the earlie

22 Flow across the esophagogastric junction (EGJ) is strongly related to op

23 Distensibility of the esophagogastric junction (EGJ) largely determines esopha

24 etailed analysis of the mechanics leading to esophagogastric junction (EGJ) opening during transient

25 ip between obesity and the morphology of the esophagogastric junction (EGJ) pressure segment using hi

26 f achalasia hinges on demonstrating impaired esophagogastric junction (EGJ) relaxation and aperistals

27 Obstruction at the esophagogastric junction (EGJ) results in esophageal dil

28 ximal stomach above the meal adjacent to the esophagogastric junction (EGJ), referred to as the 'acid

29 pic specialized intestinal metaplasia of the esophagogastric junction (SIM-EGJ).

30 nitial laparotomy, followed by harvesting of esophagogastric junction 60 days later.

31 with esophageal adenocarcinoma (EAC) and/or esophagogastric junction adenocarcinoma after local ther

32 The stage of esophageal or esophagogastric junction adenocarcinoma after neoadjuvan

33 zed consecutive resections for esophageal or esophagogastric junction adenocarcinomas performed at tw

34 management of most resectable esophageal and esophagogastric junction adenocarcinomas.

35 3-85.15 years) with biopsy-proved cancer (28 esophagogastric junction and 71 gastric cancers) were ex

36 is capable of selectively analyzing discrete esophagogastric junction contributors (lower esophageal

37 in short segments of columnar mucosa at the esophagogastric junction has clinical importance but can

38 , and the development of diagnoses including esophagogastric junction outflow obstruction and hyperco

39 Reduction or normalization of the esophagogastric junction relaxation pressure achieved by

40 that the disease process progresses from the esophagogastric junction to the esophageal body.

41 Capillary content of the esophagogastric junction was quantified using IHC for va

42 adenocarcinomas arising in the esophagus and esophagogastric junction, 56 Barrett adenocarcinomas, an

43 ders, injection of inert substances into the esophagogastric junction, and electrical stimulation of

44 ssion in adenocarcinomas of the esophagus or esophagogastric junction, few studies have assessed the

45 carcinoma of the esophagus (n = 19), cardia (esophagogastric junction, n = 12), or subcardia (n = 6).

46 th resectable adenocarcinoma of the stomach, esophagogastric junction, or lower esophagus to either p

47 epends on alleviating the obstruction at the esophagogastric junction, the postintervention contracti

48 the work-up for patients with tumors of the esophagogastric junction.

49 tion of adenocarcinomas of the esophagus and esophagogastric junction.

50 for adenocarcinoma of the esophagus and the esophagogastric junction.

51 ip of the nasogastric tube was lodged at the esophagogastric junction.

52 the treatment of patients with esophageal or esophagogastric-junction cancer is not well established.

53 ients with potentially curable esophageal or esophagogastric-junction cancer.

54 risks of esophageal adenocarcinoma (EAC) and esophagogastric junctional adenocarcinoma (EGJA).

55 significant dose and duration responses) and esophagogastric junctional adenocarcinoma (odds ratio =

56 n total, 581 participants with EAC, 213 with esophagogastric junctional adenocarcinoma, and 332 with

57 ogic subtypes of esophageal malignancy (EAC, esophagogastric junctional adenocarcinoma, and ESCC) in

58 ssessed and data from 5 index (aortic, major esophagogastric, liver, pancreatic, and pelvic resection

59 VTEs occurred postdischarge (from 17.9% for esophagogastric to 100% for endocrine operations).

60 athy, malnutrition, muscle wasting, ascites, esophagogastric variceal hemorrhage, spontaneous bacteri

61 ic complications in patients with documented esophagogastric varices undergoing OLT.

62 e TEE monitoring during OLT in patients with esophagogastric varices.